Albert Qin
Overview
Explore the profile of Albert Qin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mascarenhas J, Bose P, Hillis C, Yacoub A, Chaer F, Maze D, et al.
Acta Haematol
. 2025 Mar;
:1-11.
PMID: 40043697
Ropeginterferon alfa-2b-njft (ropeg) was approved and recommended as a preferred cytoreductive treatment for polycythemia vera (PV). The approved regimen requires an initial dose of 100 μg or 50 μg if...
2.
Yacoub A, Abu-Zeinah G, Qin A, Tashi T, Dana W, Shih W, et al.
Ann Hematol
. 2025 Jan;
104(1):335-345.
PMID: 39804351
Polycythemia vera (PV) is characterized by clonal hematopoietic stem or progenitor cells with constitutively active somatic mutation(s) in the Janus kinase 2 gene. Phlebotomy (Phl) and aspirin are often used...
3.
Qin A, Zhang L, Jin J
Br J Haematol
. 2025 Jan;
206(3):986-987.
PMID: 39800983
No abstract available.
4.
Kirito K, Qin A, Suo S, Fu R, Wu D, Sato T, et al.
BJC Rep
. 2024 Nov;
2(1):51.
PMID: 39516248
No abstract available.
5.
Suo S, Fu R, Qin A, Shao Z, Bai J, Zhou H, et al.
Br J Haematol
. 2024 Oct;
205(6):2510-2514.
PMID: 39462216
No abstract available.
6.
Qin A, Wu D, Liao J, Xie S, Chen H, Gao Y, et al.
Front Pharmacol
. 2024 Oct;
15:1455979.
PMID: 39386026
Ropeginterferon alfa-2b (Ropeg) is approved for the treatment of adults with polycythemia vera (PV). This report aims to analyze the ethnic sensitivity of Ropeg for the treatment of PV, comparing...
7.
Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera
Kirito K, Sugimoto Y, Gotoh A, Takenaka K, Ichii M, Inano T, et al.
Int J Hematol
. 2024 Oct;
120(6):675-683.
PMID: 39361233
Ropeginterferon alfa-2b (ropegIFN), a new-generation interferon-based agent, has been approved in Japan for patients with polycythemia vera (PV) who are ineligible for or respond inadequately to conventional treatment. However, long-term...
8.
9.
Xu X, Yan S, Yo Y, Chiang P, Tsai C, Lin L, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272910
Programmed cell death 1 (PD-1) and programmed death-ligand 1 (PD-L1) interact to form an immune checkpoint fostering viral infection and viral oncogene-induced tumorigenesis. We generated a novel anti-human PD-1, humanized...
10.
Abu-Zeinah G, Qin A, Gill H, Komatsu N, Mascarenhas J, Shih W, et al.
Ann Hematol
. 2024 Aug;
103(9):3573-3583.
PMID: 39145781
Primary myelofibrosis (PMF) is the most aggressive of the myeloproliferative neoplasms and patients require greater attention and likely require earlier therapeutic intervention. Currently approved treatment options are limited in their...